Skip to content

Reservoir Neuroscience

3 viewers · 30d

Total raised

$3.0M

+$3.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $3.0M
ROUNDS
1
INVESTORS
2
FOUNDED
N/A
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Reservoir Neuroscience is a preclinical biotech developing small-molecule therapeutics that repair the blood-brain barrier and reverse brain vascular pathology in aging and neurodegenerative disease. Co-founded in 2019 by UC Berkeley PhD neuroscientists Aaron Friedman and Vlad Senatorov, the company operates in the San Francisco Bay Area. It uses a proprietary human organ-on-chip platform that grows human blood vessels to model vascular aging and screen compounds. Reservoir says it has identified a first-in-kind compound that reverses disease in blood vessels and repairs barrier damage.

What sets it apart

Rather than targeting amyloid or tau, Reservoir treats brain vascular dysfunction and blood-brain barrier breakdown as the upstream driver of neurodegeneration, and discovers against it on a human organ-chip model instead of animal models.

Funding history

1 round
EquityJun 8, 2026
Form D
+$3.0M$3.0M total

Latest SEC filings

via EDGAR · CIK 0001878332
Form D · Jun 8, 2026NewView on EDGAR

Products

1 tracked

Blood-brain barrier repair program

Preclinical CNS therapeutics

A preclinical therapeutic candidate discovered on Reservoir's human vascular organ-chip platform that reverses degenerative changes in brain blood vessels and repairs the damaged blood-brain barrier.

  • First-in-kind compound targeting brain vascular disease rather than protein aggregates
  • Reverses vascular pathology and associated neuroinflammation
  • Discovered on a human organ-on-chip vascular aging model
  • Aimed at age-related neurodegeneration and cognitive decline

Links

WebsiteLinkedInSEC EDGAR filings